Species-dependent hepatic metabolism of immunosuppressive agent tacrolimus (FK-506)

References

• Armitage JM, Fricker FJ, Del Nido P, Cipriani L, Starzl TE. (1991a). The clinical trial of FK 506 as primary and rescue immunosuppression in pediatric cardiac transplantation. Transplant Proc 23(6):3058–60.
   PubMed Web of Science ®Google Scholar
• Armitage JM, Kormos RL, Fung J, Starzl TE. (1991b). The clinical trial of FK 506 as primary and rescue immunosuppression in adult cardiac transplantation. Transplant Proc 23(6):3054–7.
   PubMed Web of Science ®Google Scholar
• Armitage JM, Kormos RL, Griffith BP, Hardesty RL, Fricker FJ, Stuart RS, Marrone GC, Todo S, Fung J, Starzl TE. (1991c). A clinical trial of FK 506 as primary and rescue immunosuppression in cardiac transplantation. Transplant Proc 23(1 Pt 2):1149–52.
   PubMed Web of Science ®Google Scholar
• Christians U, Pokaiyavanichkul T, Chan L. (2006). Tacrolimus. In Burton M, Shaw LM, Schentag JJ, Evans WE, editors. Applied pharmacokinetics and pharmacodynamics – principles of therapeutic drug monitoring. 4th Ed. Philadelphia, PA: Lippincott Williams & Wilkins. p. 529–562.
   Google Scholar
• Christians U, Radeke HH, Kownatzki R, Schiebel HM, Schottmann R, Sewing KF. (1991). Isolation of an immunosuppressive metabolite of FK506 generated by human microsome preparations. Clin Biochem 24(3):271–5.
   PubMed Web of Science ®Google Scholar
• Firdaous I, Verbeeck R, Hassoun A, Langrehr J, Wallemacq P. (1997). Excretion of tacrolimus glucuronides in human bile. Eur J Drug Metab Pharmacokinet 22(3):217–21.
   PubMed Web of Science ®Google Scholar
• Fung JJ, Todo S, Tzakis A, Alessiani M, Abu-Elmagd K, Jain A, Bronster O, Martin M, Gordon R, Starzl TE. (1991). Current status of FK 506 in liver transplantation. Transplant Proc 23(3):1902–5.
   PubMed Web of Science ®Google Scholar
• Gusev AI, Wilkinson WR, Proctor A, Hercules DM. (1995). Improvement of signal reproducibility and matrix/comatrix effects in MALDI analysis. Analyt Chem 67(6):1034–41.
   Google Scholar
• Hunt SA. (2000). New immunosuppressive agents in clinical use: mycophenolate mofetil and tacrolimus. Cardiol Rev 8(3):180–4.
   PubMedGoogle Scholar
• Iwasaki K. (2007). Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics. Drug Metab Pharmacokinet 22(5):328–35.
   PubMed Web of Science ®Google Scholar
• Jain A, Venkataramanan R, Sharma R, Kwong T, Orloff M, Abt P, Kashyap R, Tsoulfas G, Batzold P, Williamson M et al. (2008). Pharmacokinetics of tacrolimus in living donor liver transplant and deceased donor liver transplant recipients. Transplantation 85(4):554–60.
   PubMed Web of Science ®Google Scholar
• Kelley M, Jain A, Kashyap R, Orloff M, Abt P, Wrobble K, Venkataramanan R, Bozorgzadeh A. (2005). Change in oral absorption of tacrolimus in a liver transplant recipient after reversal of jejunoileal bypass: case report. Transplant Proc 37(7):3165–7.
   PubMed Web of Science ®Google Scholar
• Kelly PA, Burckart GJ, Venkataramanan R. (1995). Tacrolimus: a new immunosuppressive agent. Am J Health Syst Pharm 52(14):1521–35.
   PubMed Web of Science ®Google Scholar
• Lhoest G, Maton N, Laurent A, Verbeeck RK. (1994a). Isolation and identification of a FK-506 C36–C37 dihydrodiol from erythromycin-induced rabbit liver microsomes. J Pharm Biomed Anal 12(2):235–41.
   PubMed Web of Science ®Google Scholar
• Lhoest G, Maton N, Verbeeck R. (1992). Isolation and mass spectrometric identification of two metabolites of FK 506 from rat liver microsomal incubation media. Pharm Acta Helv 67(9–10):270–4.
   PubMedGoogle Scholar
• Lhoest G, Maton N, Verbeeck RK. (1993). Isolation and identification of a novel isomerized epoxide metabolite of FK-506 from erythromycin- induced rabbit liver microsomes. Drug Metab Dispos 21(5):850–4.
   PubMed Web of Science ®Google Scholar
• Lhoest G, Wallemacq P, Verbeeck R. (1991). Isolation and mass spectrometric identification of five metabolites of FK-506, a novel macrolide immunosuppressive agent, from human plasma. Pharm Acta Helv 66(11):302–6.
   PubMedGoogle Scholar
• Lhoest GJ, Maton N, Latinne D, Laurent A, Verbeeck RK. (1994b). 15-Desmethyl FK-506 and 15,31-desmethyl FK-506 from human liver microsomes: isolation, identification (by fast atom bombardment mass spectrometry and NMR), and evaluation of in vitro immunosuppressive activity. Clin Chem 40(5):740–4.
   PubMed Web of Science ®Google Scholar
• Muddiman DC, Gusev AI, Proctor A, Hercules DM, Venkataramanan R, Diven W. (1994). Quantitative measurement of cyclosporin A in blood by time-of-flight mass spectrometry. Anal Chem 66(14):2362–8.
   PubMed Web of Science ®Google Scholar
• Reichenspurner H. (2005). Overview of tacrolimus-based immunosuppression after heart or lung transplantation. J Heart Lung Transplant 24(2):119–30.
   PubMed Web of Science ®Google Scholar
• Schuler W, Christians U, Schimieder P, Schiebel H-M, Holze I, Sewing K-F, Kessler H. (1993). Structural investigations of 13-O-demethyl-FK506 and its isomers generated by in vitro metabolism of FK506 using human-liver microsomes. Helv Chim Acta 76(6):2288–302.
   Google Scholar
• Shapiro R, Jordan M, Fung J, McCauley J, Johnston J, Iwaki Y, Tzakis A, Hakala T, Todo S, Starzl TE. (1991a). Kidney transplantation under FK 506 immunosuppression. Transplant Proc 23(1 Pt 2):920–3.
   PubMed Web of Science ®Google Scholar
• Shapiro R, Jordan M, Scantlebury V, Fung J, Jensen C, Tzakis A, McCauley J, Carroll P, Ricordi C, Demetris AJ et al. (1991b). FK 506 in clinical kidney transplantation. Transplant Proc 23(6):3065–7.
   PubMed Web of Science ®Google Scholar
• Shiraga T, Matsuda H, Nagase K, Iwasaki K, Noda K, Yamazaki H, Shimada T, Funae Y. (1994). Metabolism of FK506, a potent immunosuppressive agent, by cytochrome P450 3A enzymes in rat, dog and human liver microsomes. Biochem Pharmacol 47(4):727–35.
   PubMed Web of Science ®Google Scholar
• Starzl TE, Murase N, Demetris AJ, Ildstad S, Ricordi C, Trucco M. (1993). Allograft and xenograft acceptance under FK-506 and other immunosuppressant treatment. Ann N Y Acad Sci 685:46–51.
   PubMed Web of Science ®Google Scholar
• Stiff DD, Venkataramanan R, Prasad TN. (1992). Metabolism of FK 506 in differentially induced rat liver microsomes. Res Commun Chem Pathol Pharmacol 78(1):121–4.
   PubMedGoogle Scholar
• Tata PNV, Subbotina N, Burckart GJ, David C, Muddiman DC, Gusev AI, Hercules DM, Venkataramanan R. (Forthcoming 2009). Metabolism of tacrolimus (FK-506) in baboon liver microsomes. Res Commun Mol Pathol Pharmacol (submitted).
   Google Scholar
• Thomson AW. (1991). The immunosuppressive macrolides FK-506 and rapamycin. Immunol Lett 29(1–2):105–11.
   PubMed Web of Science ®Google Scholar
• Venkataramanan R, Swaminathan A, Prasad T, Jain A, Zuckerman S, Warty V, McMichael J, Lever J, Burckart G, Starzl T. (1995). Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 29(6):404–30.
   PubMed Web of Science ®Google Scholar
• Vincent SH, Karanam BV, Painter SK, Chiu SH. (1992). In vitro metabolism of FK-506 in rat, rabbit, and human liver microsomes: identification of a major metabolite and of cytochrome P450 3A as the major enzymes responsible for its metabolism. Arch Biochem Biophys 294(2):454–60.
   PubMed Web of Science ®Google Scholar
• Warty V, Zuckerman S, Venkataramanan R, Lever J, Chao J, McKaveney T, Fung J, Starzl T. (1995). Tacrolimus analysis: a comparison of different methods and matrices. Ther Drug Monit 17(2):159–67.
   PubMed Web of Science ®Google Scholar